Anorectal Malformations and the Risk of Colorectal Cancer—Is Early Routine Endoscopic Screening Indicated?

European Journal of Pediatric Surgery ◽

10.1055/s-0040-1718749 ◽

2020 ◽

Author(s):

Anna Svenningsson ◽

Anna Gunnarsdottir ◽

Tomas Wester

Keyword(s):

Colorectal Cancer ◽

Early Adulthood ◽

Anorectal Malformations ◽

Population Based ◽

Observational Period ◽

Endoscopic Screening ◽

Medical Birth Register ◽

National Patient ◽

And Gender

Abstract Introduction Colorectal cancer (CRC) has been reported in early adulthood in patients with anorectal malformation (ARM), and therefore, the need of endoscopic controls has been discussed. The aim of this study was to assess the risk of CRC in patients with ARM. Materials and Methods This was a nationwide population-based study with data from Swedish national health care registers. All patients diagnosed with ARM born in Sweden between 1964 and 1999 were identified in the National Patient Register. The same group was followed up in the Swedish Cancer Register from birth to December 31, 2014, for occurrences of CRC. Five age- and gender-matched individuals randomly selected from the Medical Birth Register served as controls for each ARM patient born between 1973 and 1999. Results A total of 817 patients (474 males) with ARM were included and followed up from birth to the end of observational period. Time of follow-up ranged from 15 to 50 years (mean: 28 years). None of the patients was diagnosed with CRC during the observational period. One case of rectal cancer and one case of sigmoid cancer were detected among the 3,760 controls. Conclusion In our study, the risk of CRC in early adulthood in patients with ARM is low. Our result does not support routine endoscopic follow-up for patients with ARM during the first decade of life.

Download Full-text

A microRNA panel compared to environmental and polygenic scores for colorectal cancer risk prediction

Nature Communications ◽

10.1038/s41467-021-25067-8 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Janhavi R. Raut ◽

Ben Schöttker ◽

Bernd Holleczek ◽

Feng Guo ◽

Megha Bhardwaj ◽

...

Keyword(s):

Colorectal Cancer ◽

Risk Prediction ◽

Risk Score ◽

Characteristic Curve ◽

Predictive Ability ◽

Population Based ◽

Polygenic Risk Score ◽

Nucleotide Polymorphisms ◽

Polygenic Scores

AbstractCirculating microRNAs (miRNAs) could improve colorectal cancer (CRC) risk prediction. Here, we derive a blood-based miRNA panel and evaluate its ability to predict CRC occurrence in a population-based cohort of adults aged 50–75 years. Forty-one miRNAs are preselected from independent studies and measured by quantitative-real-time-polymerase-chain-reaction in serum collected at baseline of 198 participants who develop CRC during 14 years of follow-up and 178 randomly selected controls. A 7-miRNA score is derived by logistic regression. Its predictive ability, quantified by the optimism-corrected area-under-the-receiver-operating-characteristic-curve (AUC) using .632+ bootstrap is 0.794. Predictive ability is compared to that of an environmental risk score (ERS) based on known risk factors and a polygenic risk score (PRS) based on 140 previously identified single-nucleotide-polymorphisms. In participants with all scores available, optimism-corrected-AUC is 0.802 for the 7-miRNA score, while AUC (95% CI) is 0.557 (0.498–0.616) for the ERS and 0.622 (0.564–0.681) for the PRS.

Download Full-text

Initial participation as a predictor for continuous participation in population-based colorectal cancer screening

Journal of Medical Screening ◽

10.1177/0969141317717757 ◽

2017 ◽

Vol 25 (3) ◽

pp. 126-133 ◽

Cited By ~ 5

Author(s):

Deborah Saraste ◽

Daniel J Öhman ◽

Marika Sventelius ◽

K Miriam Elfström ◽

Johannes Blom ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Screening ◽

Colorectal Cancer Screening ◽

Strong Predictor ◽

Participation Rate ◽

Occult Blood ◽

Population Based ◽

Faecal Occult Blood Testing ◽

Faecal Occult

Objectives To assess patterns and probabilities of participation in multiple rounds of colorectal cancer screening. Methods All individuals who were invited to participate in population-based colorectal cancer screening in the Stockholm-Gotland region in Sweden between 1 January 2008 and 30 September 2015 were included in the study. Guaiac-based faecal occult blood testing was used. All individuals invited to the three first consecutive screening rounds were included in the analysis. Results There were 346,168 individuals eligible for invitation to screening. The average participation rate during the follow-up period was 60%. Eligible individuals could be invited 1–4 times, depending on age at first invitation. Of 48,959 individuals invited to the three first consecutive rounds of screening, 71% participated at least once, and 50% participated in all three rounds. Participation at first invitation was a predictor for participation in subsequent rounds, and the likelihood of continuous participation following participation in the first round was 84%. Of those who attended the first and second rounds, 93% also participated in the third round. Similar patterns of consistency were seen among non-participants. For individuals not participating in the first screening round, the likelihood of consistent non-participation was 71. Conclusions Participation in the first round of screening is a strong predictor for participation in subsequent rounds. Therefore, reducing barriers for initial participation is a key for achieving consistent participation over several rounds in organized colorectal cancer screening programmes.

Download Full-text

Sa1180 Low Incidence of Post-Colonoscopy Colorectal Cancer During Six Years of Follow-up: A Population-Based Cohort Study

Gastroenterology ◽

10.1016/s0016-5085(13)60786-6 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-221-S-222

Author(s):

Ilhame Ben Larbi ◽

Arend J. Buth ◽

Veerle M. Coupe ◽

René W. van der Hulst ◽

Pieter Scholten ◽

...

Keyword(s):

Colorectal Cancer ◽

Cohort Study ◽

Population Based ◽

Low Incidence

Download Full-text

Predictors of uptake of aspirin (ASA) chemoprevention in Lynch syndrome (LS).

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.3_suppl.49 ◽

2021 ◽

Vol 39 (3_suppl) ◽

pp. 49-49

Author(s):

Michael J. Hall ◽

Margie Clapper ◽

Wen-Chi J Chang ◽

Yana Chertock ◽

Minhhuyen J Nguyen

Keyword(s):

Older Age ◽

Prevention Measures ◽

Chi Square ◽

Endoscopic Screening ◽

Written Information ◽

And Gender ◽

Few Data ◽

Medical Recommendations ◽

Ethnicity And Gender

49 Background: Substantial data support efficacy of ASA in colorectal adenoma and cancer (CRC) chemoprevention. In 2011, the CaPP2 Phase 3 trial showed benefit of 600 mg ASA daily for prevention of LS-associated CRC (HR 0.41,p=0.02) in persons w/ASA adherence >2 yrs. Anecdotally, uptake of ASA by LS pts has been low, but few data exist. We examined uptake and predictors of ASA chemoprevention among LS pts receiving follow-up at our center since 2011. Methods: Pts evaluated by Fox Chase’s Risk Assessment Program receive in-person medical recommendations and written information about cancer (CA) prevention measures including ASA. Medical records of 127 LS pts were retrospectively reviewed. Demographics, gene affected, personal Hx of CA, ASA use, and ASA dose were collected. Majority (94.5%) of cohort had documentation of ongoing LS endoscopic screening at our center—only 3.2% had no recent follow-up (past 3 yrs) and 2.4% had recently died (past 3 yrs). Chi-square tests and multivariable logistic regression were used in analyses. Results: Overall 24.4% (31/127) of pts reported ASA use for chemoprevention (see Table). Nearly half (48.4%) of ASA users took 81 mg ASA daily, and only 22.6% reported taking >600 mg ASA daily. ASA use was associated with older age, MLH1/ MSH2+ vs MSH6/ PMS2+, and personal Hx of CRC. In the multivariable logistic model, older age (OR 2.80, p=0.04) and MLH1/ MSH2+ (OR 2.64,p=0.07) were significant and borderline significant, respectively. Adding race/ethnicity and gender strengthened the effect of age>60 (OR 3.11, p=0.03), and improved fit (pseudoR2=16.8%). Conclusions: Uptake of ASA chemoprevention by LS pts is overall modest, but older age is associated with ASA uptake for chemoprevention. Among ASA users, fewer than 1 in 4 take the 600 mg daily dose shown effective in CaPP2. Confirmatory trials as well as efforts to elucidate barriers to ASA chemoprevention in LS are needed. [Table: see text]

Download Full-text